-
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis : the AMBITION studyJones, G., dr.med. ...Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibitssignalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. Objective: To evaluate through the AMBITION ... study the efficacy and safety of tocilizumab monotherapy versus methotrexate in patients with active RA for whom previous treatment with methotrexate/biological agents had not failed. Methods: This 24-week, double-blind, double-dummy, parallel-group study, randomised 673 patients to either tocilizumab 8 mg/kg every 4 weeks, ormethotrexate, starting at 7.5 mg/week and titrated to 20 mg/week within 8 weeks, or placebo for 8 weeks followed by tocilizumab 8 mg/kg. The primary end point was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at week 24. Results: The intention-to-treat analysis demonstrated that tocilizumab was better than methotrexate treatment with a higher ACR20 response (69.9 vs 52.5%; p<0.001), and 28-joint Disease Activity Score (DAS28) <2.6 rate (33.6 vs 12.1%) at week 24. Mean high-sensitivity C-reactive protein was within the normal range from week 12 with tocilizumab, whereas levels remained elevated with methotrexate. The incidence of serious adverse events with tocilizumab was 3.8% versus 2.8% withmethotrexate (p = 0.50), and of serious infections, 1.4% versus 0.7%, respectively. There was a higher incidence of reversible grade 3 neutropenia (3.1% vs 0.4%) and increased total cholesterol > or =240 mg/dl (13.2% vs 0.4%), and a lower incidence of alanine aminotransferase elevations >3x-<5x upper limit of normal (1.0% vs 2.5%), respectively. Conclusion: Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement inRA signs and symptoms, and a favourable benefit-risk, in patients for whom treatment with methotrexate or biological agents has not previously failed.Source: Annals of the Rheumatic Diseases. - ISSN 0003-4967 (Letn. 69, št. 1, 2010, str. 88-96)Type of material - article, component partPublish date - 2010Language - englishCOBISS.SI-ID - 27277017
Author
Jones, G., dr.med. |
Sebba, A. |
Gu, JR |
Tomšič, Matija, 1959-
Topics
Adult |
Aged |
Antibodies, Monoclonal |
Adverse Effects |
Therapeutic Use |
Antirheumatic Agents |
Adverse Effects |
Therapeutic Use |
Arthritis, Rheumatoid |
Blood |
Drug Therapy |
Biological Markers |
Blood |
C-Reactive Protein |
Metabolism |
Double-Blind Method |
Immunosuppressive Agents |
Adverse Effects |
Therapeutic Use |
Methotrexate |
Therapeutic Use |
Adverse Effects |
Severity Of Illness Index |
Treatment Outcome |
Dvojnoslepa metoda |
Protitelesa monoklonska |
Artritis revmatični |
Starostniki |
Odrasli |
Biološki označevalci |
Imunosupresivi |
Metotreksat |
Indeks resnosti bolezni |
Zdravljenje, izid |
C-reaktivna beljakovina |
Antirevmatiki
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
| Year | Impact factor | Edition | Category | Classification | ||||
|---|---|---|---|---|---|---|---|---|
| JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP | |
Impact factor
Select the library membership card:
DRS, in which the journal is indexed
| Database name | Field | Year |
|---|
| Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
|---|---|
| Jones, G., dr.med. | ![]() |
| Sebba, A. | ![]() |
| Gu, JR | ![]() |
| Tomšič, Matija, 1959- | 13601 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
| Pickup location | Material status | Reservation |
|---|
Please wait a moment.
